Open to Accrual

 

BTCRC-BRE15-024
  • Study Title: A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024 (NCT03090165)
  • Status: Open to Accrual
  • Study Details: See BTCRC-BRE15-024 study page
BTCRC-GI21-500
  • Study Title: A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination with Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI21-500 (NCT05624918)
  • Status: Open to Accrual
  • Study Details: See BTCRC-GI21-500 study page
BTCRC-GI22-564
  • Study Title: Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers: Big Ten Cancer Research Consortium BTCRC-GI22-564 (NCT06048133)
  • Status: Open to Accrual
  • Study Details: See BTCRC-GI22-564 study page
BTCRC-GI22-588
  • Study Title: A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer (NCT06493019)
  • Status: Open to Accrual
  • Study Details: See BTCRC-GI22-588 study page
BTCRC-HEM15-027
  • Study Title: Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027 (NCT03681561)
  • Status: Open to Accrual
  • Study Details: See BTCRC-HEM15-027 study page
BTCRC-HN17-111
  • Study Title: Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111 (NCT03942653)
  • Status: Open to Accrual
  • Study Details: See BTCRC-HN17-111 study page
BTCRC-LUN18-153
  • Study Title: A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153 (NCT04317534)
  • Status: Open to Accrual
  • Study Details: See BTCRC-LUN18-153 study page
BTCRC-LUN20-462
  • Study Title: A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second Line Treatment for Small Cell Lung Cancer (NCT04919382)
  • Status: Open to Accrual
  • Study Details: See BTCRC-LUN20-462 study page
BTCRC-LYM20-463
  • Study Title: A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma (NCT05551936)
  • Status: Open to Accrual
  • Study Details: See BTCRC-LYM20-463 study page

 

Closed to Accrual

 

BTCRC-AML17-113
  • Study Title: Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113 (NCT04070768)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-AML17-113 study page
BTCRC-BRE16-042
  • Study Title: A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042 (NCT03393845)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-BRE16-042 study page
BTCRC-BRE18-337
  • Study Title: Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337 (NCT03911973)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-BRE18-337 study page
BTCRC-BRE19-409
  • Study Title: A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409 (NCT04762979)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-BRE19-409 study page
BTCRC-GI15-067
  • Study Title: A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067 (NCT03861702)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-GI15-067 study page
BTCRC-GI20-457
  • Study Title: A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial) Big Ten Cancer Research Consortium BTCRC-GI20-457 (NCT04829383)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-GI20-457 study page
BTCRC-LUN16-081
  • Study Title: Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) (NCT03285321)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-LUN16-081 study page
BTCRC-LUN18-363
  • Study Title: A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363 (NCT04699838)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-LUN18-363 study page
BTCRC-LUN19-396
  • Study Title: A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396 (NCT04367311)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-LUN19-396 study page

 

Completed Studies

 

BTCRC-BRE15-016
  • Study Title: A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016 (NCT02668666)
  • Status: Completed
  • Study Details: See BTCRC-BRE15-016 study page
BTCRC-ESO14-012
  • Study Title: A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012 (NCT02639065)
  • Status: Completed
  • Study Details: See BTCRC-ESO14-012 study page
BTCRC-GU14-003
  • Study Title: Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003 (NCT02348008)
  • Status: Completed
  • Study Details: See BTCRC-GU14-003 study page
BTCRC-GI15-015
  • Study Title: A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015 (NCT03283761)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-GI15-015 study page
BTCRC-GU15-023
  • Study Title: Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium GU15-023 (NCT02891161)
  • Status: Completed
  • Study Details: See BTCRC-GU15-023 study page
BTCRC-GU16-043
  • Study Title: Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043 (NCT03308396)
  • Status: Completed
  • Study Details: See BTCRC-GU16-043 study page
BTCRC-GYN15-013
  • Study Title: Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma: Big Ten Cancer Research Consortium GYN15-013 (NCT02549209)
  • Status: Completed
  • Study Details: See BTCRC-GYN15-013 study page
BTCRC-LUN15-017
  • Study Title: A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy (NCT03003468)
  • Status: Completed
  • Study Details: See BTCRC-LUN15-017 study page
BTCRC-LUN15-029
  • Study Title: A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029 (NCT03083808)
  • Status: Completed
  • Study Details: See BTCRC-LUN15-029 study page
BTCRC-LUN17-127
  • Study Title: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127 (NCT03575793)
  • Status: Completed
  • Study Details: See BTCRC-LUN17-127 study page
BTCRC-LUN17-139
  • Study Title: A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139 (NCT03713944)
  • Status: Completed
  • Study Details: See BTCRC-LUN17-139 study page

 

Studies Terminated

 

BTCRC-AML18-342
  • Study Title: Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia. Big Ten Cancer Research Consortium BTCRC-AML18-342 (NCT04128020)
  • Status: Terminated
  • Study Details: See BTCRC-AML18-342 study page
BTCRC-GI13-002
  • Study Title: An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002 (NCT02575339)
  • Status: Terminated
  • Study Details: See BTCRC-GI13-002 study page
BTCRC-GI18-149
  • Study Title: Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 (NCT03997448)
  • Status: Terminated
  • Study Details: See BTCRC-GI18-149 study page
BTCRC-GI19-400
  • Study Title: Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400 (NCT04713202)
  • Status: Terminated
  • Study Details: See BTCRC-GI19-400 study page
BTCRC-GU16-051
  • Study Title: Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients: Big Ten Cancer Research Consortium BTCRC-GU16-051 (NCT03502681)
  • Status: Terminated
  • Study Details: See BTCRC-GU16-051 study page
BTCRC-GU19-404
  • Study Title: A Single Arm, Phase I/II Trial of Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men with Localized, High Risk Prostate Cancer Big Ten Cancer Research Consortium BTCRC-GU19-404 (NCT04737109)
  • Status: Terminated
  • Study Details: See BTCRC-GU19-404 study page
BTCRC-HEM15-028
  • Study Title: Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL): Big Ten Cancer Research Consortium BTCRC-HEM15-028 (NCT03547700)
  • Status: Terminated
  • Study Details: See BTCRC-HEM15-028 study page
BTCRC-HEM16-085
  • Study Title: Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma (NCT03927105)
  • Status: Terminated
  • Study Details: See BTCRC-HEM16-085 study page
BTCRC-HEM17-092
  • Study Title: Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092 (NCT04079738)
  • Status: Terminated
  • Study Details: See BTCRC-HEM17-092 study page
BTCRC-LYM17-145
  • Study Title: Phase Ib dose de-escalation study of the PI3K alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma. Big Ten Cancer Research Consortium BTCRC-LYM17-145 (NCT04431635)
  • Status: Terminated
  • Study Details: See BTCRC-LYM17-145 study page